Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.40 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29561309 | 1.00 | IDO1 (0.46) | IDO1NR3C1NOTUMADCY8ADCY1 | |
| Carbamic Acid SCHEMBL11790168 | 0.87 | TAS2R14 (0.44) | IDO1NR3C1NOTUMADCY8ADCY1 | |
| SCHEMBL19903979 | 0.84 | NR3C1 (0.42) | IDO1NR3C1CHRM3ACHE | |
| SCHEMBL26375379 | 0.83 | NOTUM (0.46) | NOTUMADCY8ADCY1S1PR1PDE3B | |
| SCHEMBL10170297 | 0.81 | NR3C1 (0.40) | NR3C1CHRM3ACHE | |
| SCHEMBL299182 | 0.81 | IDO1 (0.41) | IDO1P2RX7HSD11B1ACHETRPA1 | |
| SCHEMBL21346441 | 0.78 | AR (0.50) | ADCY8ADCY1 | |
| SCHEMBL5949403 | 0.78 | NOTUM (0.53) | NOTUMS1PR1TAS2R14PDE3BPDE3A | |
| SCHEMBL30742957 | 0.78 | NOTUM (0.53) | NOTUMS1PR1TAS2R14PDE3BPDE3A | |
| SCHEMBL30742956 | 0.78 | NOTUM (0.53) | NOTUMS1PR1TAS2R14PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 419 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183239-B1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-22 | — | — | EP | claimed |
| US-8153682-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-10 | — | — | US | claimed |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-22 | — | — | US | claimed |
| US-7470701-B2 | Substituted 2,5-heterocyclic derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | claimed |
| US-20080255120-A1 | SUBSTITUTED 2,5-HETEROCYCLIC DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-10-16 | — | — | US | claimed |
| EP-1732919-A1 | SUBSTITUTED THIOPHENE DERIVATIVES AS ANTI-CANCER AGENTS | CHIRON CORPORATION (US) | 2006-12-20 | — | — | EP | claimed |
| US-20050256121-A1 | e.g. 3-(4-fluorophenyl)-N-{5-[2-(methylamino)pyrimidin-4-yl]thien-2-yl}propanamide; PKB/Akt kinase inhibitor; anticarcinogenic agent; carcinoma, cancer metastases, squamous cell carcinoma, esophageal squamous cell carcinoma, oral carcinoma, cutaneous T cell lymphoma, Hodgkin's lymphoma | CHIRON CORPORATION (US) | 2005-11-17 | — | — | US | claimed |
| WO-2005095386-A1 | SUBSTITUTED THIOPHENE DERIVATIVES AS ANTI-CANCER AGENTS | CHIRON CORPORATION (US) | 2005-10-13 | — | — | WO | claimed |
| US-6495540-B2 | HEXAHYDROAZEPINE-2-ONE DERIVATIVE AS BETA-AMYLOID INHIBITOR | BRISTOL - MYERS SQUIBB PHARMA COMPANY | 2002-12-17 | — | — | US | claimed |
| US-20020010172-A1 | Lactams as inhibitors of A-beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-24 | — | — | US | claimed |
| CN-114269756-B | 4-Oxo-3, 4-dihydropyrido [3,4-D ] pyrimidine compounds that inhibit EIF4E | 效应疗法股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2024050016-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2024-03-07 | — | — | WO | disclosed |
| EP-4289846-A1 | HETEROCYCLIC COMPOUND, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022213204-A9 | CARBOXAMIDE PYROLOPYRAZINE AND PYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF MYT1 AND USE THEREOF IN THE TREATMENT OF CANCER | REPARE THERAPEUTICS INC. (CA) | 2023-11-16 | — | — | WO | disclosed |
| EP-4273147-A1 | SUBSTITUTED SPIROLACTAMS, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2023-11-08 | — | — | EP | disclosed |
| WO-2001072324-A1 | LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-10-04 | — | — | WO | disclosed |
| WO-2000039088-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-07-06 | — | — | WO | disclosed |
| EP-0481317-B1 | Method for dechlorination and/or debromination of aromatic compounds containing fluorine with chlorine and/or bromine | BAYER AG (DE) | 1995-08-09 | — | — | EP | disclosed |
| US-5283378-A | Process for the dechlorination and/or debromination of fluorine-and chlorine- and/or bromine-containing aromatic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1994-02-01 | — | — | US | disclosed |
| EP-0481317-A2 | Method for dechlorination and/or debromination of aromatic compounds containing fluorine with chlorine and/or bromine | BAYER AG (DE) | 1992-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256121-A1 | e.g. 3-(4-fluorophenyl)-N-{5-[2-(methylamino)pyrimidin-4-yl]thien-2-yl}propanamide; PKB/Akt kinase inhibitor; anticarcinogenic agent; carcinoma, cancer metastases, squamous cell carcinoma, esophageal squamous cell carcinoma, oral carcinoma, cutaneous T cell lymphoma, Hodgkin's lymphoma | MALT1, AKT1, PIK3CA | IDO1 3135/4885NR3C1 1879/4885NOTUM 970/4885 |
| US-20080255120-A1 | SUBSTITUTED 2,5-HETEROCYCLIC DERIVATIVES | CYP3A5, ABCG2, ABCB1 | IDO1 1747/4885NR3C1 1808/4885NOTUM 767/4885 |
| US-20020010172-A1 | Lactams as inhibitors of A-beta protein production | BACE1, APP, APH1A | IDO1 2498/4885NR3C1 4799/4885NOTUM 300/4885 |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | IDO1 4477/4885NR3C1 2769/4885NOTUM 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.